{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:24Z","timestamp":1786982844019,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Pasireotide LAR (PAS-LAR) was released in Italy in 2017 to treat acromegaly patients resistant to SRLs (Somatostatin Receptors Ligands). The long-term follow-up data of PAS-LAR therapy in Italy are limited. This study aimed to evaluate the efficacy and safety of PAS-LAR in acromegaly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Patients with acromegaly in PAS-LAR treatment were enrolled in three tertiary Italian endocrinological centers and evaluated by a retrospective observational real-life multicentre study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients have been studied before (baseline) and 1, 6, 12, 24 and\u2009&gt;\u200936\u00a0months after PAS-LAR start. Clinical, biochemical, and pituitary magnetic resonance data were collected, along with information on adverse events. Acromegaly disease activity was classified according to the IGF-1 index (normal value\u2009&lt;\u20091.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty patients (female 23) were enrolled. PAS-LAR treatment (mean follow-up 24\u2009\u00b1\u200916\u00a0months) significantly decreased IGF-1 levels (IGF-1 index baseline vs last visit: 1.9\u2009\u00b1\u20090.6 vs 1.2\u2009\u00b1\u20090.6,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). At the last visit, 67% of patients had controlled disease, and 44% showed a decrease in tumor volume. Clinical and biochemical efficacy was observed as early as after 1-month of PAS-LAR treatment (IGF-1 index baseline vs 1-month: 1.9\u2009\u00b1\u20090.6 vs 1.4\u2009\u00b1\u20090.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Also, 50% of patients referred headache improvement or disappearance. Fifteen patients discontinued PAS-LAR due to failure of treatment and poor glycaemic control. The prevalence of diabetes increased from 33% at the baseline to 54% at the last visit (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0072).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In real-life settings, PAS-LAR significantly decreases symptoms, IGF-1 levels, and the size of adenoma in patients with acromegaly resistant to SRLs. Beneficial effects may occur early after the first injection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-023-02275-1","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:02:17Z","timestamp":1705708937000},"page":"1733-1741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up"],"prefix":"10.1007","volume":"47","author":[{"given":"C.","family":"Urbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dassie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zampetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Maffei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bogazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,20]]},"reference":[{"issue":"8","key":"2275_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.2174\/1871530320666200129113328","volume":"20","author":"R Cozzi","year":"2020","unstructured":"Cozzi R et al (2020) Italian Association of Clinical Endocrinologists (AME) and Italian AACE chapter position statement for clinical practice: acromegaly - Part 2: Therapeutic Issues. EMIDDT 20(8):1144\u20131155. https:\/\/doi.org\/10.2174\/1871530320666200129113328","journal-title":"EMIDDT"},{"key":"2275_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-022-09710-3","author":"M Bolanowski","year":"2022","unstructured":"Bolanowski M et al (2022) Pasireotide-a novel somatostatin receptor ligand after 20\u00a0years of use. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-022-09710-3","journal-title":"Rev Endocr Metab Disord"},{"key":"2275_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00931","author":"M Gadelha","year":"2020","unstructured":"Gadelha M et al (2020) Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2019.00931","journal-title":"Front Endocrinol"},{"issue":"11","key":"2275_CR4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/jcph.326","volume":"54","author":"S Petersenn","year":"2014","unstructured":"Petersenn S et al (2014) Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. J Clin Pharmacol 54(11):1308\u20131317. https:\/\/doi.org\/10.1002\/jcph.326","journal-title":"J Clin Pharmacol"},{"key":"2275_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A et al (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791\u2013799","journal-title":"J Clin Endocrinol Metab"},{"key":"2275_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-016-0096-8","author":"MD Bronstein","year":"2016","unstructured":"Bronstein MD et al (2016) Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocr Disord. https:\/\/doi.org\/10.1186\/s12902-016-0096-8","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"2275_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","volume":"182","author":"A Colao","year":"2020","unstructured":"Colao A et al (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol 182(6):583. https:\/\/doi.org\/10.1530\/EJE-19-0762","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2275_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12020-016-1182-4","volume":"55","author":"M Fleseriu","year":"2017","unstructured":"Fleseriu M et al (2017) Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine 55(1):247\u2013255. https:\/\/doi.org\/10.1007\/s12020-016-1182-4","journal-title":"Endocrine"},{"issue":"11","key":"2275_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875\u2013884. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2275_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","volume":"18","author":"M Sheppard","year":"2015","unstructured":"Sheppard M et al (2015) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary 18(3):385\u2013394. https:\/\/doi.org\/10.1007\/s11102-014-0585-6","journal-title":"Pituitary"},{"issue":"12","key":"2275_CR11","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"Gadelha MR et al (2020) Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect 9(12):1178\u20131190. https:\/\/doi.org\/10.1530\/EC-20-0361","journal-title":"Endocr Connect"},{"issue":"2","key":"2275_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/jc.2017-02017","volume":"103","author":"A Muhammad","year":"2018","unstructured":"Muhammad A et al (2018) Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). J Clin Endocrinol Metabol 103(2):586\u2013595. https:\/\/doi.org\/10.1210\/jc.2017-02017","journal-title":"J Clin Endocrinol Metabol"},{"issue":"5","key":"2275_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/EJE-18-0353","volume":"179","author":"A Muhammad","year":"2018","unstructured":"Muhammad A et al (2018) Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. Eur J Endocrinol 179(5):269\u2013277. https:\/\/doi.org\/10.1530\/EJE-18-0353","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2275_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","volume":"62","author":"I Shimon","year":"2018","unstructured":"Shimon I et al (2018) Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 62(2):448\u2013455. https:\/\/doi.org\/10.1007\/s12020-018-1690-5","journal-title":"Endocrine"},{"issue":"10","key":"2275_CR15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1530\/EC-19-0332","volume":"8","author":"H Lasolle","year":"2019","unstructured":"Lasolle H et al (2019) Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study. Endocr Connect 8(10):1383\u20131394. https:\/\/doi.org\/10.1530\/EC-19-0332","journal-title":"Endocr Connect"},{"issue":"1","key":"2275_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-021-01185-w","volume":"25","author":"M Stelmachowska-Bana\u015b","year":"2022","unstructured":"Stelmachowska-Bana\u015b M et al (2022) Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation. Pituitary 25(1):180\u2013190. https:\/\/doi.org\/10.1007\/s11102-021-01185-w","journal-title":"Pituitary"},{"key":"2275_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.633944","author":"P Witek","year":"2021","unstructured":"Witek P et al (2021) The effect of 6 months\u2019 treatment with pasireotide LAR on glucose metabolism in patients with resistant acromegaly in real-world clinical settings. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2021.633944","journal-title":"Front Endocrinol"},{"issue":"2","key":"2275_CR18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12020-021-02782-2","volume":"74","author":"A Akirov","year":"2021","unstructured":"Akirov A et al (2021) Long-term safety and efficacy of long-acting pasireotide in acromegaly. Endocrine 74(2):396\u2013403. https:\/\/doi.org\/10.1007\/s12020-021-02782-2","journal-title":"Endocrine"},{"issue":"11","key":"2275_CR19","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1210\/jc.2019-00825","volume":"104","author":"S Chiloiro","year":"2019","unstructured":"Chiloiro S et al (2019) Pasireotide and pegvisomant combination treatment in acromegaly resistant to second-line therapies: a longitudinal study. J Clin Endocrinol Metabol 104(11):5478\u20135482. https:\/\/doi.org\/10.1210\/jc.2019-00825","journal-title":"J Clin Endocrinol Metabol"},{"issue":"6","key":"2275_CR20","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1210\/jc.2018-01979","volume":"104","author":"EC Coopmans","year":"2019","unstructured":"Coopmans EC et al (2019) How to position pasireotide LAR treatment in acromegaly. J Clin Endocrinol Metabol 104(6):1978\u20131988. https:\/\/doi.org\/10.1210\/jc.2018-01979","journal-title":"J Clin Endocrinol Metabol"},{"issue":"7","key":"2275_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S2213-8587(19)30181-0","volume":"7","author":"AF Daly","year":"2019","unstructured":"Daly AF et al (2019) Shrinkage of pituitary adenomas with pasireotide. Lancet Diabetes Endocrinol 7(7):509. https:\/\/doi.org\/10.1016\/S2213-8587(19)30181-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2275_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1365-2265.2011.04019.x","volume":"75","author":"CN Jayasena","year":"2011","unstructured":"Jayasena CN, Comninos AN et al (2011) The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol (Oxf) 75(2):220\u2013225. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04019.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2275_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s12020-023-03325-7","volume":"80","author":"A Giampietro","year":"2023","unstructured":"Giampietro A, Menotti S et al (2023) De-escalation treatment with pasireotide for acromegaly: a long-term experience. Endocrine 80(3):505\u2013510. https:\/\/doi.org\/10.1007\/s12020-023-03325-7","journal-title":"Endocrine"},{"key":"2275_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-219686","author":"CM Lovato","year":"2018","unstructured":"Lovato CM, Kapsner PL (2018) Analgesic effect of long-acting somatostatin receptor agonist pasireotide in a patient with acromegaly and intractable headaches. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2017-219686","journal-title":"BMJ Case Rep"},{"issue":"5","key":"2275_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ghir.2015.07.003","volume":"25","author":"D Marina","year":"2015","unstructured":"Marina D et al (2015) Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues\u2013Observations in two patients with acromegaly and severe headache. Growth Hormone IGF Res 25(5):262\u2013267. https:\/\/doi.org\/10.1016\/j.ghir.2015.07.003","journal-title":"Growth Hormone IGF Res"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02275-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02275-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02275-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T23:47:38Z","timestamp":1722642458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02275-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["2275"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02275-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,20]]},"assertion":[{"value":"7 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Padua Local Ethics Committee (number 5520\/AO\/22). This study involve human participants only.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"All participants provided informed consent prior to their participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}